MitraClip patient selection: inclusion and exclusion criteria for optimal outcomes

Gössl, Mario; Sorajja, Paul

doi:10.21037/acs.2018.08.04

Cited by 17 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared with the restrictive inclusion criteria of the EVEREST trial (20, 21), nowadays more patients with challenging anatomy are referred for percutaneous edge-to-edge repair (22). Except for a mitral valve orifice area (MVOA) <4 cm 2 in COAPT, no specific anatomic exclusion criteria are applied in the most recent randomized trials, MITRA-FR (9) and COAPT (5).…”

Section: Introductionmentioning

confidence: 99%

Complications Following Percutaneous Mitral Valve Repair

Gheorghe

Ielasi

Rensing

et al. 2019

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Mitral valve disease affects more than 4 million people in the United States and it is the second most prevalent valvulopathy in Europe. The gold standard of treatment in these patients is surgical repair or mitral valve replacement. In the last decade, numerous transcatheter therapies have been developed to overcome the increased number of subjects with symptomatic severe mitral regurgitation and high surgical risk. The Mitraclip (Abbott Vascular, Menlo Park, CA), PASCAL (Edwards Lifesciences, Irvine, CA, USA), the Carillon™ Mitral Contour System™ (Cardiac Dimension Inc., Kirkland, WA, USA), the Mitralign™ (Mitralign, Tewksbury, Massachusetts), and the Cardioband (Edwards Lifesciences, Irvine, CA) are the principal percutaneous devices for mitral valve repair. We present an evidence-based clinical update that provides an overview of these technologies and their potential complications.

show abstract

Section: Introductionmentioning

confidence: 99%

Complications Following Percutaneous Mitral Valve Repair

Gheorghe

Ielasi

Rensing

et al. 2019

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Indeed, comparisons of three-dimensional (3D) transesophageal echocardiography and cardiac CT have shown that both imaging modalities provide good detailing of mitral leaflet morphology ( 58 ). In addition, calcification and clefts of the leaflets are important to note as these can preclude adequate transcatheter edge to edge repair (TEER) ( 59 ).…”

Section: Mitral Intervention Planningmentioning

confidence: 99%

Cardiac Computed Tomography: Application in Valvular Heart Disease

Patel

Vandermolen

Herrey

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The incidence and prevalence of valvular heart disease (VHD) is increasing and has been described as the next cardiac epidemic. Advances in imaging and therapeutics have revolutionized how we assess and treat patients with VHD. Although echocardiography continues to be the first-line imaging modality to assess the severity and the effects of VHD, advances in cardiac computed tomography (CT) now provide novel insights into VHD. Transcatheter valvular interventions rely heavily on CT guidance for procedural planning, predicting and detecting complications, and monitoring prosthesis. This review focuses on the current role and future prospects of CT in the assessment of aortic and mitral valves for transcatheter interventions, prosthetic valve complications such as thrombosis and endocarditis, and assessment of the myocardium.

show abstract

“…Recommended criteria for selecting patients who are suitable to TMVR are reported elsewhere. 18 All patients received PFTs during primary investigation, which is a mandatory part of standard operating procedures (SOPs) at our institution. Wholebody plethysmography (MasterLab, Viasys) was performed before and after bronchodilation according to current guidelines and recommendations.…”

Section: Patients' Selectionmentioning

confidence: 99%

Safety and efficacy of transcatheter mitral valve repair in patients with COPD; results from real‐world cohort

Alachkar

Müller

Alnaimi

et al. 2022

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objective To evaluate the safety and efficacy of transcatheter mitral valve repair (TMVR) in patients with chronic obstructive pulmonary disease (COPD). Background Heart failure and COPD share many clinical features and commonly coexist. Data about the safety and efficacy of TMVR in patients with COPD is not conclusive. Methods Three hundred and forty consecutive patients undergoing TMVR were retrospectively included. COPD diagnosis was based on pulmonary function tests (PFTs). Intra‐hospital, 30‐day‐ and 1‐year outcomes were compared between both groups. Results Eighty‐two patients had COPD (24%). There was no difference in intra‐hospital mortality between patients with and without COPD (both 5%, p = 0.95). Among patients who had a successful procedure and survived to discharge there was a trend toward more rehospitalization due to decompensated heart failure at 30‐day follow‐up in patients with COPD (12.9% vs. 6.8%, p = 0.08) with no difference in mortality. At median follow‐up of 1 year, New York heart association (NYHA) category was comparable among both groups and there was no significant difference in rehospitalization (COPD: 29.9% vs. non‐COPD: 34%, p = 0.5). There was a trend toward increased 1‐year mortality in COPD patients (31.2% vs. 20.6%, p = 0.06). However, a composite endpoint of rehospitalization or death at 1 year did not differ between both groups (48% vs. 42.5%, p = 0.4). Regression analysis showed no correlation between COPD severity and worse TMVR outcomes. Conclusions COPD is highly prevalent among patients undergoing TMVR. However, TMVR seems to be safe and effective in COPD patients. COPD severity and PFT impairment alone should not be considered as a contraindication for TMVR.

show abstract

MitraClip patient selection: inclusion and exclusion criteria for optimal outcomes

Cited by 17 publications

References 26 publications

Complications Following Percutaneous Mitral Valve Repair

Complications Following Percutaneous Mitral Valve Repair

Cardiac Computed Tomography: Application in Valvular Heart Disease

Safety and efficacy of transcatheter mitral valve repair in patients with COPD; results from real‐world cohort

Contact Info

Product

Resources

About